	US 12,133,836 B2
	Reduction of adipose tissue
John Daniel Dobak, III, La Jolla, CA (US)
Assigned to 10XBIO, LLC, La Jolla, CA (US)
Filed by 10XBIO, LLC, La Jolla, CA (US)
Filed on Jun. 15, 2021, as Appl. No. 17/348,527.
Application 15/133,079 is a division of application No. 14/796,686, filed on Jul. 10, 2015, granted, now 9,351,945, issued on May 31, 2016.
Application 17/348,527 is a continuation of application No. 16/582,118, filed on Sep. 25, 2019, granted, now 11,065,210.
Application 16/582,118 is a continuation of application No. 15/810,964, filed on Nov. 13, 2017, granted, now 10,485,767, issued on Nov. 26, 2019.
Application 15/810,964 is a continuation of application No. 15/133,079, filed on Apr. 19, 2016, granted, now 9,844,520, issued on Dec. 19, 2017.
Claims priority of provisional application 62/165,716, filed on May 22, 2015.
Claims priority of provisional application 62/121,927, filed on Feb. 27, 2015.
Prior Publication US 2021/0378984 A1, Dec. 9, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61P 3/04 (2006.01); A61K 9/00 (2006.01); A61K 31/08 (2006.01); A61K 47/10 (2017.01); A61P 3/00 (2006.01)

CPC A61K 31/08 (2013.01) [A61K 9/0019 (2013.01); A61K 47/10 (2013.01); A61P 3/00 (2018.01)]

13 Claims

1. A pharmaceutical formulation comprising (i) polidocanol in an amount up to about 10% W/V; and (ii) a C₃-C₆alcohol in an amount from about 0.5% W/V to about 10% W/V.